Collegium Pharmaceutical (NASDAQ:COLL) Shares Down 6.5% – What’s Next?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price fell 6.5% during trading on Monday . The stock traded as low as $27.70 and last traded at $27.5610. Approximately 156,600 shares traded hands during trading, a decline of 67% from the average daily volume of 481,368 shares. The stock had previously closed at $29.47.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Piper Sandler reiterated a “neutral” rating and issued a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Needham & Company LLC cut their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $52.60.

Collegium Pharmaceutical Trading Down 4.5%

The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The company has a market cap of $845.80 million, a PE ratio of 20.95 and a beta of 0.73. The firm’s 50 day moving average is $34.60 and its 200 day moving average is $36.72.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. During the same quarter in the prior year, the firm posted $1.68 earnings per share. The business’s quarterly revenue was up 6.3% on a year-over-year basis. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in the business. Group One Trading LLC purchased a new position in Collegium Pharmaceutical in the 4th quarter worth $28,000. Caitong International Asset Management Co. Ltd increased its stake in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares during the period. PNC Financial Services Group Inc. lifted its position in Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of Collegium Pharmaceutical in the fourth quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Collegium Pharmaceutical by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 318 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.